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Chaicharn Deerochanawong1* and Alessandra Ferrario2Abstract
Management of diabetes represents an enormous challenge for health systems at every level of development. The
latter are tested for their ability to continuously deliver high quality care to patients from the day they are
diagnosed throughout their life. In this study, we review the status of diabetes management in Thailand and try to
identify the key challenges the country needs to address to reduce the current (and future) medical and economic
burden caused by the disease.
We conducted a literature review on the burden, costs, and outcomes of diabetes in Thailand. This information was
complemented by personal communication with senior officials in the Thai Ministry of Health.
We identified the following priorities for the future management of diabetes in Thailand. First, increasing screening
of diabetes in high risk population and promoting annual screening of diabetes complications in all diabetic
patients. Second, identifying and addressing factors affecting poor treatment outcomes. Third, policy should specify
clear targets and provide and use a monitoring framework to track progress. Fourth, efforts are needed to further
improve data availability. Up-to-date data on the medical and economic burden of diabetes representative at the
national level and at least the regional level are essential to identify needs and monitor progress towards
established targets. Fifth, promotion of a healthy lifestyle for prevention of diabetes through education and quality
information delivered to the public.Background
Thailand is an upper-middle income country in South-East
Asia which has achieved impressive economic, social, and
health improvements in the past ten years. Between 2007
and 2011 its gross domestic product grew by 7.8%, the per-
centage of people living below poverty line decreased from
21% to 8.1% between 2000 and 2009, and under-five mor-
tality reached a record low for a country with 13 deaths
per 1000 live births in 2010 [1].
The country’s disease burden and demographic profile
stand out from the South East Asia region’s average for its
high prevalence of non-communicable diseases (NCDs),
higher than the average regional prevalence of HIV/AIDS,
and an ageing population [2].
Non-communicable diseases are estimated to account for
71% of all deaths with cardiovascular diseases representing
27%, cancers 12%, and diabetes 6% of all deaths [3]. Com-
municable diseases are estimated to account for 24% of the* Correspondence: chaicharn_dee@hotmail.com
1Rajavithi hospital, College of Medicine, Rangsit University, Ministry of Public
Health, Bangkok 10400 Thailand
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distribution, and reproduction in any mediumtotal years of life lost (regional average 49%) while non-
communicable diseases account for 55% (regional average
36%) [3].
Life expectancy in 2009 was 70 years (66 for males
and 74 for females) [4]. The total fertility rate has de-
creased from 2.4 in 1990 to 1.6 in 2006 [5]. In terms of
age structure (based on 2009 figures), 22% of the Thai
population was below age 15 and 11% above age 60, the
population median age was 33.
Many factors have contributed to these remarkable
health achievements and among these, increased access to
health care through universal health insurance is probably
one of the key ones. Thailand was the first country in the
region able to achieve universal health coverage of its
population. Universal health coverage was achieved in
2002 after 27 years of progressive expansion of the univer-
sal coverage (UC) scheme to include all the uninsured to-
gether with the beneficiaries of the former medical welfare
scheme for the poor, the elderly, the disabled and the chil-
dren, and the voluntary health insurance scheme for the
informal sector [6]. This scheme is financed through gen-
eral taxation and covers 75% of the Thai population [7].e BioMed Central Ltd. This is an Open Access article distributed under the terms
(http://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 1 Literature review results
Area of diabetes
management
Number of
references
retrieved
References
Prevalence and incidence 17 [11,12,16-25,27-29,33,34]
Mortality 2 [35,36]
Cost of diabetes 6 [37,38,52,60-62]
Prevalence of complications 15 [13,15,49-51,53,60,63-70]
Cost of complications 4 [38,52,60,61]
Outcomes 6 [50,53,63,67,71,72]
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vants medical benefit scheme, financed through general
tax and a non-contributory scheme, and the social secu-
rity scheme which is financed by equal contributions
from employer, employee and the government [8]. In
2010, these two schemes covered 9% and 16% of the
population respectively [8].
In terms of the benefit package, the UC scheme covers
for in-patient and out-patient care, prescription drugs,
laboratory investigations, simple dental care procedures,
disease prevention, health promotion, several expensive
treatments such as radio- and chemotherapy, surgical
procedures, and emergency treatment [7]. Since the end
of 2008, renal replacement therapy including renal and
peritoneal dialysis and kidney transplantation is also cov-
ered by the UC scheme although a co-payment per
haemodialysis session is required [9].
Very little information is available on medicines avail-
ability in Thailand. According to a survey using the
standard WHO/HAI methodology, in 2006 metformin
was available in more than 80% of the surveyed public
(20 hospitals) and private (21 private retail pharmacies)
health facilities [10]. Diabetes medicine such as metfor-
min, sulfonyurea and insulin are available to all diabetes
patients free of charge as part of the UC scheme.
Management of diabetes represents an enormous chal-
lenge for health systems at every level of development.
The latter are tested for their ability to continuously de-
liver high quality care to patients from the day they are
diagnosed throughout their life. Achieving this requires
good coordination across different areas of health care,
different levels of care, in addition to trained human re-
sources, an efficient supply system for medicines, a reli-
able health information system, national and international
policies and strategies, and an equitable financing system
which ensures access to essential health care services.
In this study, we review the status of diabetes manage-
ment in Thailand and try to identify the key challenges
the country needs to address to reduce the current (and
future) medical and economic burden caused by the dis-
ease. To do that, we review evidence on the burden of
diabetes, including the available data sources, available
diagnostic and screening programmes, diabetes treat-
ment, costs and outcomes, and policies implemented.
Methodology
This study is based on secondary data analysis comple-
mented by primary data collection. A literature review
of peer-reviewed and grey literature including policy doc-
uments and annual reports of the MoPH and govern-
ment statistics was undertaken. The following key words
were used on the 21st of February 2012 PubMed ((dia-
betes[Title]) AND Thailand[Title/Abstract]) OR (("Dia-
betes Mellitus"[Mesh] OR "Diabetes Mellitus, Type2"[Mesh] OR "Diabetes Mellitus, Type 1"[Mesh]) AND
"Thailand"[Mesh]). Studies presenting data on prevalence,
incidence, mortality, outcomes (testing, screening rates),
and complications were included. We excluded studies
which did not present disaggregated data on diabetes (e.g.
studies on chronic disease including diabetes). Evidence
from the systematic literature review was complemented
by primary data obtained through personal communica-
tion with Thai diabetes experts and senior public health
officials from the Bureau of Non-Communicable Diseases
(NCDs) and the Bureau of Policy and Strategy in the Thai
Ministry of Public Health (MoPH).Results
The search strategy yielded 267 papers, of which 194
were excluded through title and 37 through abstract
screening because they did not meet the inclusion cri-
teria. There were 46 final peer-reviewed papers included
in the review (Table 1).Data sources on the burden of diabetes
National health examination survey (NHES)
There is no national longitudinal diabetes registry in
Thailand and the main source of prevalence data for dia-
betes is the national health examination survey (NHES).
The aim of the NHES is to estimate the prevalence of
particular health conditions and risk factors including
obesity, diabetes, and mental, reproductive and elderly
health. This survey was completed for the fourth time in
2009 (previous surveys were conducted in 1991, 1997,
2004). In 2009, a national representative sample of 20,450
(39,290 in 2009) individuals aged 15 and over was ran-
domly selected using a four-stage sampling strategy from
five provinces in each of the four regions and Bangkok.
Diabetes prevalence was assessed by fasting blood glucose
test and patients identified as diabetic if they had either
FPG > = 7.0 mmol/L but lack of a previous diagnosis (un-
diagnosed diabetes) or a previous diagnosis of diabetes
and intake of glucose lowering drugs during the past two
weeks (diagnosed diabetes) [11,12].
Figure 1 Prevalence of diabetes mellitus in Thailand, 1991-2009.
Source: 1991, 1997, 2004, 2009 NHES I-IV. Notes: M: males, F: females.
All estimates refer to people aged 15 and over. Diabetes was
defined as FPG≥ 126 mg/dl or previous diagnosis of diabetes and
use of medication during the past two weeks.
Deerochanawong and Ferrario Globalization and Health 2013, 9:11 Page 3 of 18
http://www.globalizationandhealth.com/content/9/1/11Diabetes registry project
In April 2003, 9,419 diabetes patients (both Type 1 and 2)
from eleven tertiary care hospitals overall Thailand were
enrolled in the Thailand diabetes registry (TDR) project
[13]. This project was a collaboration between the Clinical
Research Cooperation Network (CRCN) and the Health
System Research Institute (HSRI), supported by the En-
docrine Society of Thailand. The first objective of this
registry was to identify the characteristics of Thai diabetic
patients in tertiary care medical centers and to determine
the extent of long term diabetic complications. The sec-
ond objective was to develop and strengthen a clinical re-
search network in Thailand which included experts in
diabetes mellitus. The third and final objective was to col-
lect baseline data for future follow-up studies. Cross-
sectional data were collected from 11 tertiary level hospi-
tals with diabetes clinics between April and December
2003. Demographic data, clinical status of diabetes and its
complications were collected to estimate the prevalence of
complications and risk factors. Data quality was ensured
by regular on-site visits of internal and external auditors.
This project also had a second component which was a
three-year cohort study from April 2003 to February 2006
to determine the causes of death in diabetes patients.
DiabCare Asia
DiabCare is an international collaboration between Novo
Nordisk Asia Pacific Pte Ltd, Singapore; BioRad Pacific,
Hong Kong; and diabetes associations in the participating
countries (Bangladesh, China, India, Indonesia, Malaysia,
Philippines, Singapore, South Korea, Sri Lanka, Taiwan,
Philippines, and Vietnam). The aim of this partnership is
to collect evidence on the disease pattern, management,
control status, and complications of diabetes in the Asian
diabetes population. Patients were recruited in hospitals
and followed for 8 to 9 months depending on the study
year. DiabCare Asia studies were conducted in 1998 [14],
1991, 2001, 2003, 2008. The next data collection round is
planned in late 2012- early 2013. Thailand was surveyed
during the 1998, 2001 [15], 2003, and 2008 rounds.
International collaborative study of cardiovascular disease
in Asia (InterASIA)
The InterASIA study on diabetes prevalence, risk factors
for cardiovascular diseases, and diabetes management was
conducted in 2000 in Thailand and China. This study,
founded by Pfizer was a collaboration between universities
in Australia, China, Thailand, and the US. The study was
based on a nationally representative sample of the Thai
general population [16].
Other studies
Several other studies have been conducted on the bur-
den of diabetes in Thailand. These include investigationson the incidence [17,18] and prevalence of diabetes in
population sub-groups [19], prevalence [20,21] and inci-
dence [22-26] of diabetes Type 1 in children, incidence
[27] and prevalence [28-30] of gestational diabetes, and
prevalence of type 2 diabetes in women with polycystic
ovary syndrome [31]. Other studies looked at the preva-
lence of complications in the Thai diabetes population.
Prevalence and incidence
Prevalence of diabetes mellitus type 2
Data from the four NHES indicate that prevalence of
diabetes in individuals aged 15 and over has increased
over time from 2.3% in 1991 to 4.6% in 1997, to 6.8% in
2004, and to 6.9% in 2009 [32] (Figure 1). According to
NHES 2009 and 2004, women experienced a higher preva-
lence than men [11,12]. In contrast, findings from the
InterASIA study in 2000 did not identify any difference
in diabetes prevalence between men and women aged 35
and over (9.3% men vs. 9.9% women, p = 0.6) [16]. At the
other end, an earlier studya among Shinawatra employees,
a group of relatively young individuals with high socio-
economic status, found a higher prevalence in men (2.2%,
N = 1,250) than in women (0.1%, N = 2,365) [19].
According to the NHES 2009, prevalence of diabetes
was higher in urban areas in comparison to rural areas
(P < 0.001 for both sexes) [11]. However, findings from
NHES 2004, only found a statistically significant higher
prevalence in urban men, in comparison to their rural
counterparts, (P < 0.001) but not in urban women (p > 0.05)
[12]. The existence of a difference in diabetes prevalence
between urban and rural areas in Thailand was confirmed
by findings from the InterASIA study in 2000 (12.1% urban
vs. 8.4% rural, p = 0.01, in individuals aged 35 and over)
[16]. No difference between urban and rural areas was
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survey in 2004 [12,16].
Different studies on diabetes prevalence in Thailand
agree that the prevalence of diabetes increases with age and
reaches a peak at some point after age 55 depending on the
study [11,12,16,19].
An important problem in diabetes care is under-diagnosis
as it delays start of treatment and exposes the patient to the
risk of complications which leads to higher treatment costs.
Levels of under-diagnosis improved between 2004 and
2009 and this improvement was more evident in women
than men. Nevertheless, a large proportion of total diabetes
patients remains undiagnosed (from 66.5% to 47.3% in men
and from 51.4% to 23.4% in women between 2004 and
2009) [11].
Findings from the NHES 2009 suggest that women have
better rates of diagnosis in comparison to men and this dif-
ference was statistically significant (there was a difference
also in 2004 but this was not statistically significant) [11,12].
However, the InterASIA study did not find a statistically
significant difference in the proportion of diagnosed patient
by gender (53% women vs. 47% men, p = 0.4) but it found
that diagnosis rate was higher for people aged 55 and over
(63% > =55 years old vs. 37% <54 years old, p = 0.01) [16].
A comparison of the findings from the NHES in 2009
with results from 2004, shows that the proportion of in-
dividuals with diabetes and concomitant hypertension
did not significantly decrease in 2009 in both sexes [11].
However, the proportion of women with diabetes who
were either abdominally obese or had high total choles-
terol (≥5.2 mmol/L) increased from 18% in 2004 toFigure 2 Incidence of diabetes mellitus type 1 in children aged 0-15.
Results from a study in Bangkok were not included as they were not comp
employed [24]. There was another study looking at the seasonal variation i
rates but only total number of cases in one hospital which made it unsuita
calculated by dividing the total number of cases reported by hospitals with
obtained from retrospective postal survey or medical record analysis and n
summarising the results of the regional studies mentions that the criteria in
Classification of Diabetes Mellitus were used.23.5% in 2009 and this difference was significant (both
P < 0.01) [11].
An earlier study on the prevalence of DMT2 in children
and adolescents (mean age 11.6 years) reported an in-
crease from 5.8% to 13.3% between 1986 and 1995 [21].
The authors suggest a link between this increase and the
concomitant increase in obesity from 5.8% to 13.3% be-
tween 1990 and 1996 [21].
Incidence of diabetes mellitus type 1 in children
Incidence of type 1 diabetes in children in North-East
Thailand has increased over the years from in 0.17 per
100,000 in 1984 to 0.3 in 1995, to 0.39 in 2000 and 1.27
in 2005. In the other regions it has also grown although
following a less linear trend particularly in the Central
region (Figure 2).
Findings from a study in the Bangkok-Noi district in
Bangkok, found an extremely small number of cases
(maximum 1 per year) between 1991 and 1995 which, des-
pite the size of the child population in this district, it still
resulted in the highest prevalence rates for type 1 diabetes
recorded in the country (2.18 per 100,000 in 1991, 0 in
1992, 1.97 in 1993, 2.06 in 1994, and 2.04 in 1995) [24].
Another study looked at the seasonal variation of diabetes
type 1 and found that the peak seasons were the winter and
the summer season and lower during the rainy season [20].
This was explained by the higher prevalence of infections
in the winter season and the higher levels of pollution in
the summer in comparison to the rainy season [20].
All studies (apart from the Bangkok study which did not
discuss gender differences) on diabetes type 1 identifiedSources [22-26]:. Secondary results from Tuchinda et al. 2002. Notes:
arable with the other studies due to the different methodology
n DMT1 which was not included because it did not report incidence
ble to calculate population incidence rates [20]. Incidence was
the total child population in the hospitals’ catchment area. Data were
o information on the diagnostic criteria used was provided. A study
the 1997 Report of the Expert Committee on the Diagnosis and
Figure 3 Prevalence of gestational diabetes. Notes: 1987-1989:
gestation week not specified, NDDG criteria; 1994-95: 24-28 week of
gestation, 1.4% NDDG criteria, 15.7% WHO criteria; 2001: 5.3% before
20 week of gestation, NDDG criteria; 2001: 4.9% additional at
28-32 weeks of gestation, NDDG criteria; March 2003-January 2005: mean
gestational age 26.8 weeks, NDDG criteria, only women aged 30-34.
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from 1.3 to 2. However, none of them tested for statistical
significance. Peak age at onset was 10-14 in North and
North-East region [22,25,26], 11-15 in the South region
[23], and 9-12 in Bangkok [24].
Incidence of diabetes mellitus type 2 in adults
We identified three studies on incidence of DMT2 in
adults in urban Thailand from a high socio-economic
background [17,18,33]. All the three studies used the
diagnostic criteria from the American Diabetes Associ-
ation (ADA) using fasting plasma glucose tests (FPGs),
in addition to that one study also used oral glucose toler-
ance tests (OGTTs). The most recent study was among
professionals and office workers in Bangkok and found an
incidence rate in the age-group 35-60, of 17.8 per 1000
person-years (PY) in men and 9.2 per 1000 PY in women
in 2005 [17]. A second study among university hospital
employees in Bangkok reported an incidence of 13.6 per
1000 PY in men and 6.4 per 1000 PY in women between
2001 and 2005. The study participants were over 35 years
old and predominantly female (three-quarters). High BMI
(>25 kg/m2), elevated FPG (> = 96 mg/dl) and alanine
aminotransferase levels (> 18 mg/dl) were shown to be in-
dependent predictors of DMT2 [18]. Risk of diabetes in
men was approximately twice as high as in women but
this apparent association was confounded by higher BMI
and FPG levels in men and the crude rates showed there
was no association between gender and DMT2 [18]. Find-
ings from this study were supported by an earlier study
which found an overall incidence of 11.3 per 1000 PY
among employees of a state enterprise in Bangkok be-
tween 1985 and 1997 [33].
Gestational diabetes
Four studies on the prevalence of gestational diabetes
mellitus (GDM) were identified [27-29,34]. They were hos-
pital based (one hospital per study) and mostly used the
diagnostic criteria of the National Diabetes Data Group
(NDDG), (50 g + 100 g OGTT) with one study also com-
paring NDDG results with WHO criteria (75 g OGTT).
All hospitals were located in Bangkok (Figure 3).
The highest prevalence (15.7%) was estimated in 1995
for women in their 24th to 28th week of gestation using
WHO criteria [34]. When using NDDG criteria, the same
study estimated a remarkably lower prevalence of 1.4%
[34]. Another study highlighted the importance of the
timing of diagnosis, 5.3% of screened pregnant women
were diagnosed with gestational diabetes before their 20th
gestational week and an additional 4.9% of previously un-
diagnosed women were identified in a second round of
testing during their 28th to 32nd week of pregnancy [27].
The 1987-1989 study followed a sub-sample of women
after delivery by performing an OGTT using WHO criteria4-6 weeks after childbirth. Results showed that 42.2% of
the 71 women tested had abnormal carbohydrate toler-
ance, 7% had diabetes and 35.2% impaired glucose toler-
ance (IFG) [28].
The most recent study (March 2003-January 2005)
aimed to assess the percentage of pregnancies with GDM
which were missed at the time the study was conducted
because clinical guidelines in the study hospital limit
screening to women at high risk of developing GDM. Eli-
gibility criteria for screening included pregnant women
with at least one of the following risk-factors: aged 35 and
over, family history of diabetes, previous birth over 4 kg,
and other known risk-factors of GDM. This study showed
that the prevalence of women aged 30 to 34 was 5.7%, and
that of the 32 cases identified, 12 had one risk factor, one
had two risk factors (1). More importantly 18 cases of
GDM showed no risk factors and would have been missed
due to the recommendations in the hospital’s guidelines at
the time of the study [29].
Mortality
Results of a comprehensive study to verify causes of death
using medical records and verbal autopsy methods, sug-
gest that the leading cause of death in both men and
women in 2005 was stroke (9.4% and 11.3% respectively)
[35]. Diabetes was the second cause of death in women
(8.0%) and the tenth cause of death in men (3.2%) in 2005
[35]. This difference is partly explained by the high mor-
tality levels due to road accidents and HIV/AIDS in men.
This study also highlighted issues with vital registration
where a high percentage of deaths were classified as ill-
defined. Adjustments to vital registration data led to im-
portant changes in the proportion of deaths due to HIV/
AIDS, ischaemic heart disease, and diabetes [35]. The
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maximum at age 50-79. In 2005, they represented the
main cause of death in females (12.3%) and seventh in
males (5.4%) in this age group [36].
Costs
Using a micro-costing approach, a study including 475
patients receiving treatment in a hospital in North-East
Thailand estimated a median cost of illness per patient
of USD 140 (mean USD 881) in 2008 (1 USD = 32 THB,
at 2008 prices) [37]. The total annual cost included 23%
direct medical costs, 40% direct non-medical costs, and
37% indirect costs [37]. Direct medical costs were driven
by inpatient service costs (11% of total cost of illness),
while direct non-medical cost were dominated by the
cost of informal care (28% of total cost of illness). Cost of
permanent disability (19% of total cost of illness) was the
most important contributor to informal cost [37]. The
median cost of illness increased with age (p-value < 0.001),
duration of the disease (p-value < 0.001), the level of
fasting blood glucose level (p-value = 0.002) and number
of co-morbidities (p-value = 0.0013) [37]. The median
cost of DMT1 was higher than DMT2 (USD 748 vs. USD
140), however this difference was not statistically signifi-
cant (p = 0.167 [37]).
The monthly median cost of informal care based on a
sample of 190 informal care givers was estimated at USD$
27 using an opportunity cost approach and USD$ 23 using
the proxy good method [38]. Cost of informal care contrib-
uted 28% of total cost of illness of diabetes [37] (Table 2).
Findings from one hospital showed that the cost of in-
formal care accounted for 28% of the total cost of diabetes
[38]. This is likely to have negative repercussions on labour
force participation of informal carers who dedicated on
average 112 hours per month to informal care and were in
their most productive age (25-54 years old) [38].
Diabetes screening and prevention
Recently, Thailand launched the new “Thailand Healthy
Lifestyle Strategy 2011-2020 Plan” endorsed by the Ministry
of Public Health [39]. This plan aims to decrease the preva-
lence, complications, disability, mortality and cost of illness
of five major non-communicable diseases including dia-
betes, hypertension, ischemic heart disease, stroke and can-
cer. The strategies proposed include: healthy public policy,
social mobilization and public communication, community
building, surveillance and care system including screening
diabetes in high risk population, and capacity building [39].
Yet, to-date, there is still no national screening and no
prevention programme in place. There are some exam-
ples of successful sub-national diabetes screening and
prevention initiatives. These include a prevention model
for diabetes in primary care, an educational programme on
diabetes prevention for community health care workers,and use of a mobile health unit to screen people living in
rural areas for chronic and other health conditions [40-44].
Another example is the development of a simple diabetes
risk score to identify Thai patients at high risk of develop-
ing diabetes. This score is based on a set of variables (age,
BMI, waist circumference, hypertension, and history of
diabetes in parents or siblings) which were identified as
being significant predictors of diabetes [33]. Measurement
of these variables does not require laboratory tests, making
the model a cost-effective instrument to identify high risk
people to be screened.
However, despite these initiatives have shown initial
positive results, they not really been taken beyond the
initial pilot phase.Diabetes treatment
Thailand has its own guidelines for diabetes treatment
(only available in Thai) [45] endorsed by the Thai Dia-
betes Association, the Endocrine Society of Thailand,
and the Ministry of Public Health. The guidelines are
updated every three to four years and the latest version
was published in 2011. More than 5,000 copies have been
published and distributed to primary and secondary care
physicians in all the regions of Thailand and they are also
available online. However, there is no evidence on how
many physicians have adopted these guidelines.
The Thai guidelines resemble the WHO/IDF guide-
lines [46,47], particularly with reference to screening,
prevention, treatment and monitoring. However, use of
HbA1c is not universally recommended for the diagnosis
of diabetes because of the lack of standardization of the
HbA1c measurement methodology in Thailand and FPG
is recommended instead. HbA1c is still generally recom-
mended for monitoring treatment outcomes.
To control diabetes and reduce the risk of developing
complications, it is essential to optimise physiological
values such as glycaemic levels and blood pressure and
to perform regular examinations for nephropathy (albumin
excretion, serum creatine), retinopathy (eye), neuropathy
(distal symmetric polyneuropathy), and foot disease. Evi-
dence suggests that the frequency with which these tests
are performed in Thailand is suboptimal. A study in urban
primary care clinics found that annual eye and foot exam-
ination was performed only in 21.5% and 45% of patients,
respectively [15] while the ADA recommends annual test-
ing starting at diagnosis [48].
Another study in the outpatient department of a uni-
versity hospital found that the annual eye, urine albumin
excretion, serum creatinine, and foot examination was
performed in 38.4%, 42%, 83.5%, and 17.3% of patients
in 2006 [49].
The highest rate for DMT2 patients receiving retinal
examination, 75.6% between April to December 2003, was
Table 2 Direct and indirect cost of diabetes in Thailand
Estimate Summary of the main features of the study Reference
Direct and indirect costs
Median and (mean) cost of illness per type of
patient per year
Study year: Oct 2007- Sep 2008 [60] same study as [37,38]
Independent: USD$ 124 (USD$ 598), SD 2152 Reference year for estimate is the fiscal year 2008
Disabled: USD$ 811 (USD$ 2,700), SD 4982 Setting: Waritchaphum Hospital. A 30-bed public
district hospital in Sakhon Nakhon province in
northeastern Thailand
Sample and study design: 475 randomly selected
diabetic patients. Prevalence-based cost of illness,
societal perspective
Median and (mean) cost of illness per patient
(both disabled and independent) per year:
USD 140 (USD$ 881),[82.01-552.50]
Study year: Oct 2007- Sep 2008 [37] same study as [38,60]
This included 23% of direct medical cost,
40% of direct non-medical cost,
and 37% of indirect cost
Reference year for estimate is the fiscal year 2008
Informal care contributed to 28%
of total cost of illness
Setting: Waritchaphum Hospital. A 30-bed public
district hospital in Sakhon Nakhon province in
northeastern Thailand.
Sample and study design: 475 randomly selected
diabetic patients. Prevalence-based cost of illness,
societal perspective
Direct costs
Average public treatment cost per patient
per year was USD 95
Study year: Oct 2007- Sep 2008 [62]
Drug cost was the highest cost component
(25% of total cost), followed by inpatient cost
(24%) and outpatient visit cost (17%).
Reference year for estimate is the fiscal year 2008
Setting: Waritchaphum Hospital. A 30-bed public
district hospital in Sakhon Nakhon province in
northeastern Thailand.
Sample and study design: 475 randomly selected
diabetic patients. Retrospective prevalence-based
cost of illness study, provider perspective
Annual average cost of illness (including
patients with complications):
USD$ 158 (THB 6,331)
Study year: October 2000-September 2001 [52]
Contribution to the total cost: 45% pharmacy
services, 24% outpatient services, 16% inpatient
services, 11% laboratory investigations.
Setting: 30-bed public community hospital in
central Thailand
Annual cost for DMT2 and DMT1 patients with
no complication USD$ 101 (THB 4,037) and
USD$ 251 (THB 10,059) respectively
Sample and study design: 186 diabetes patients.
Retrospective prevalence-based cost of illness study,
provider perspective
Indirect costs
Median and (mean) cost of informal care
per month
Study year: 2008 [38] same study as
Opportunity cost approach: USD 27 (USD$ 37) Setting: Waritchaphum Hospital. A 30-bed public
district hospital in Sakhon Nakhon province in
northeastern Thailand.
Proxy good method: Sample and study design: 190 informal caregivers.
Interview with carers, revealed preference method
USD$ 23 (USD 34)
Average time spent on informal care was
112 hours per month
SD: Standard deviation, [] interquartile range.
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tiary diabetes clinics [50].
Diabetes complications and cost of complications
Overall, prevalence of diabetic retinopathy (DR) ranged be-
tween 13.6-31.2% and it mostly involved non-proliferative
DR while the prevalence of diabetes nephropathy ranged
between 24-43.8% and was higher in patients with con-
comitant DR (Table 3). A variety of vascular complications
ranging from absence of foot pulse to ulcer and gangrene
leading to foot amputation and stroke were reported.
Two studies reported the prevalence of chronic kidney
diseases (CKD). A study in a primary care diabetes centre
reported a prevalence of 25-27 (depending on the esti-
mation method) for CKD stage 3-5 in 2007 [51] while a
second study in the outpatient department of a tertiary hos-
pital reported a higher prevalence (37% stage 3, 8.2 stage 4,
2.7 stage 5) in 2006 (Table 3) [49].
Complications have a major impact on the cost of dia-
betes (Table 3). A study predicted the cost of diabetes
to increase up to 232% depending on the type of compli-
cation [52].
The median cost of illness for patients with complica-
tions was significantly higher than for people without
complications (USD$ 479.93 vs. USD$ 115.12, p < 0.001)
and increased with increasing numbers of complications
(p < 0.001) [38].
Disability was a major driver of diabetes cost as well as
complications due to vascular problems leading to heart
failure and corresponding surgery.
In terms of potential savings from better prevention, a
study showed that preventing gangrene in DMT2 pa-
tients would generate almost USD$ 250 (THB 10,000)
per patient per year [52].
Diabetes outcomes
There are no national diabetes outcome indicators routinely
collected in Thailand. Some diabetes centres report out-
comes but this practice is voluntary and not standardised
across the country.
The percentage of diabetes patients who were treated
and controlled increased between 2004 and 2009 yet it
remained low in addition to showing a large gender gap
(men 7.7% in 2004 and 17.5% in 2009, women 15.8% in
2004 and 33.9% in 2009) [11]. Treatments rates for diag-
nosed patients were high leaving only 5.6% men and 1.9%
diagnosed women without treatment [11]. However, 30%
of treated men and 41% of treated women still did not at-
tain diabetes control [11].
Diabetes control in patients with high blood pressure
and high total cholesterol improved in 2009 from 3.4%
to 12.2% in men and from 6.4% to 13.8% in women for
hypertension between 2004 and 2009, 4% to 16.3% in
men and 3.8% to 17.3% in women for high cholesterolbetween 2004 and 2009 [11]. However, at the same time
the proportion of treated but not controlled patients
increased from 25.4% to 36.3% in men and from 31.3%
to 54.9% in women for hypertension and from 7.6% to
12.6% in men and from 7.0% to 18.5% in women for
high cholesterol [11].
Evidence from tertiary care units in earlier studies
(2003) shows a very high proportion of diabetes patients
with poor glycaemic control (more than 70% of diabetes
patients with HbA1c >7%) (Table 4). A more recent study
(2007) in primary care units shows a slightly better figure
(41.3% of patients with HbA1c levels <7%) (Table 4) [53].
Access to treatment and inequalities
In principle, availability of medicines to treat diabetes in
Thailand should be adequate since the universal health
coverage policy covers more than 75% of the Thai popu-
lation (the rest of the population is covered either by the
civil servant or the social security scheme). Essential dia-
betes drugs such as metformin, sulfonylurea, pioglitazone,
and insulin are included in the national drug list to which
all UC insurees have access to. However, a study on dia-
betes mortality found that patients on the UC scheme
were more likely to die than patients on the civil ser-
vice scheme (adjusted hazard ratio 1.96, 95% CI 1.48-2.58,
p-value < .005) [54]. Possible reasons for this include lower
level of education and socioeconomic status, reduced ac-
cess to lipid-lowering treatment (at the time of the study)
and renal replacement among UC insured people in com-
parison to civil servants [54,55]. When the study was
conducted between 2003 and 2006, low-cost generic
statins were not yet available. This meant that many pa-
tients were not able to access treatment because of the
high cost of the original drug. However, since the intro-
duction of generic statins and their inclusion in the UC
benefit package, this is no longer an issue.
Inequalities in access to treatment still persist in
Thailand despite universal health coverage. Renal replace-
ment therapy (RRT) for example was initially excluded
from the benefit package of the UC scheme because the
annual cost of haemodyalysis was four times higher (BHT
400,000, USD 12,100) than the price per quality-adjusted
life year threshold set by the National Health Security Of-
fice (BHT 100,000, USD 3,0000) [9]. In 2008, thanks to
pressure from patients and the public, renal replacement
therapy was finally included in the UC benefit package.
However, patients opting for haemodyialysis (which is
more expensive than peritoneal dialysis) need to pay one
third of the treatment cost out-of-pocket which corre-
sponds to an annual cost of (BHT 133,333, USD$ 4,033)
[9] in a country with a per capita gross domestic product
of USD$ 4,608 in 2010 [1]. Further, geographical barriers
can affect access to treatment and monitoring for patients
living in remote areas.
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In 2004, the Ministry of Public Health launched the
programme “Healthy Thailand” in an attempt to address
the growing burden of NCDs. This programme aimed to
promote a healthy lifestyle and to screen 60% of popula-
tion aged over 40 years to be screened for IFG and dia-
betes by the end of 2006 [12]. However, due to lack of
data, it is not clear whether this target was achieved.
Reduction of diabetes morbidity and mortality rates
due to diabetes is one of the 17 targets included in the
Health Thailand Strategy 2004-2015 [56]. However, this
target does not include measurable objectives and a
strategy to achieve this reduction.
Mobile eye care is the new project that headed by the
Ministry of Public Health to improve the access to dia-
betes care with the aim of preventing blindness from dia-
betes retinopathy. People living in rural areas often face
difficulties in accessing health care. They often have to
travel long distances and the transportation costs can be
unaffordable to many. One way of alleviating this is the
use of mobile clinics which travel to remote areas and
provide health care to where people live. The project will
be initially implemented in 11 provinces in the northern
and north-eastern of Thailand. With time, the plan is to
expand the project to cover the entire country [57].
The Thailand healthy lifestyle strategic plan (2011-2020)
lists reduction of diabetes incidence, complications, disabil-
ity, mortality, and expense as one of its five main develop-
ment goals together with reduction of hypertension, heart
disease, cerebrovascular disease and cancer [39]. This
should be achieved through the promotion of a balanced
diet, adequate physical exercise, and suitable emotional
management. However, none of the eighteen short- to
long-term performance indicators is linked to measurable
objectives in terms of disease burden and cost reduction.
Instead they simply mandate for either a reduction or an in-
crease of the relevant indicator. At a higher level, the Thai
healthy life-style strategy aims to establish political will,
raise public awareness, focus on preventive measures, seek
wider collaboration and strengthening active engagement
from all stakeholders including public and private sectors,
civil society and the general public. Finally, it also seeks to
institutionalise organizational structures at all levels of the
society, from national to village level, to serve as implemen-
tation units responsible for coordination, policy direction,
budget allocation, and monitoring and evaluation [39].
Challenges in diabetes management according to
Thai diabetes experts and senior public health
officials
The strong features of the national policy and imple-
mentation framework for diabetes prevention and con-
trol in Thailand include the existence of capable staff
and competent healthcare workers throughout Thailand,the presence of academic experts connected nationally
and internationally, effective senior level management,
strong policy development processes at the national level,
and the experience of successfully implementing the to-
bacco control programme. Weaknesses include unorga-
nised local and mid-level management, staff shortages,
high workloads in rural areas, little time or opportunity
for continuing training, and weak resource management.
Key opportunities would focus on a strong national
policy response to diabetes and other NCDs, a strong
network of competent health care workers and hospitals,
budget support from both public and private sectors,
and scientific and technical support from academics and
researchers. The main threats identified are the negative
influence of the media leading to changes in lifestyles
and increasing risks for diabetes; inconsistent and unreli-
able information about diabetes disseminated to the
public; low public awareness of diabetes issues especially
among less well educated people; and high healthcare
worker turnover in rural areas.
Discussion
Prevalence
The NHES is a nationally representative survey of the
health status of the Thai population. NHES III and IV
found a higher prevalence of DMT2 in women, older in-
dividuals, and in urban areasb. Under-diagnosis was higher
in men (2009: 47.3 vs. 23.4%, respectively; P < 0.001) [11,12]
and in those with less than secondary education [11]. Both
surveys showed that nearly all patients who were diagnosed
with diabetes were also treated with glucose-lowering medi-
cations (2004: men 2.6%, women 1.7%; 2009: men 5.6%,
women 1.9% of diagnosed patients were treated) [11]. How-
ever, despite the high treatment rates, the percentage of
treated and controlled patients (receiving treatment with
glucose-lowering medication and with FPG <7.2 mmol/L)
was still low (2004: men 7.7%, women 15.8%; 2009: men
17.5%, women 33.9% treated and controlled patients) [11].
The high percentage of treated patients among diag-
nosed diabetics suggests the availability of a resilient
health care system in terms of access to treatment. How-
ever, access is hampered by the low diagnosis rates
which need to be improved by increased screening of
high-risk groups. A risk score to identify individuals at
high-risk of developing diabetes was developed for the
Thai population [33]. Wider implementation of this low-
cost instrument can help identify high-risk individuals to
be screened and therefore to increase the percentage of
diabetes patients who is diagnosed. This would allow
earlier start of treatment and could help in preventing
part of the costs of complications arising from neglect
of the disease. Another issue is the low rates of treated
and controlled patients. To address these issues evi-
dence is needed on factors responsible for poor treatment
Table 3 Prevalence of diabetes complications in Thailand
Estimate Summary of the main features of the study Reference
Prevalence of diabetic retinopathy (DR)
15.1% DR, 11.6% non-proliferative,
3.5% proliferative DR
Study year: March-October 2007 [53]
Setting: 13 primary care units in urban areas
Sample and study design: Cross-sectional study,
ADA criteria
287 diabetic patients (79 males, 208 females)
31.2% (n = 86), 25% (n = 69) non proliferative
and 6.2% (n = 17) proliferative DR
Study year: 1 Jan-31 Dec 2006 [49]
Setting:1 tertiary hospital, out-patient department
Sample and study design: 722 diabetes patients.
Retrospective records review of DMT2 patients
31.4% (n = 2105), 22% (n = 1475) non-proliferative
and 9.4% (n = 630) proliferative DR
Study year: April-December 2003 [50]
Setting: 11 tertiary diabetes centres
Sample and study design: 6,707 diabetes Type
2 patients (4,434 females, 2,273 males). Cross-sectional,
hospital based study. Thailand diabetes registry project
DMT2 and DMT1 Study year: April-December 2003 [13]
30.7% (n = 2187), 21.3% (n-1516) non-proliferative,
9.4% (n = 671) proliferative
Setting: 11 tertiary care medical centres
Sample and study design: 9,419 diabetes patients,
65.9% females, 94.6% DMT2, 4.5% DMT1, 0.1% MODY.
Cross-sectional, hospital based study. Thailand
diabetes registry project
DMT1 Study year: April-December 2003 [63]
21.6% (n = 75), 10.9% (n = 38) non-proliferative
and 10.7% (n = 27) proliferative DR
Setting: 11 tertiary diabetes centres
Sample and study design: 347 diabetes Type
1 patients (215 females, 132 males). Cross-sectional
study of diabetes patients in 11 hospitals. Thailand
diabetes registry project.
22% (n = 667), 19% (n = 576) non-proliferative
DR, 3% (n = 91) proliferative DR
Study year: January-December 2002 [65]
Setting: All community hospital in Lampang province
Sample and study design: 3,049 diabetes patients
(838 males, 2,211 females). Cross-sectional
study in hospitals
13.6% DR Study year: 2001 [15]
Setting: 8 provincial hospitals plus 4-5 district
hospitals providing primary health care services in
each province. Total number of sites: 37
Sample and study design: 1,078 diabetes patients
(300 males, 778 females). Cross-sectional study
Comprehensive eye examination: Study year: NA [69]
19.2% non-proliferative, 1.1% proliferative
for the right eye, 18.5% non-proliferative,
1.3% proliferative for the left eye
Setting: Trang provincial hospital
Photography: Sample and study design: 714 diabetes patients.
Cross-sectional, hospital based study
23.8% NDR, 1.4% PDR for the right eye,
22.6% NDR, 1.3% PDR for the left eye
Diabetic nephropathy (DN)
DN without DR Study year: January 2007-September 2008 [68]
62.8% normo-albuminuria, 26% micro-albuminuria,
11.2% macro-albuminuria
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Table 3 Prevalence of diabetes complications in Thailand (Continued)
Setting: 7 public hospitals: Bangkok (3),
Nakhonpathom (1), Prathumthani (1),
Prathumthani (1), and Prathumthani (1)
DN and DR Sample and study design: 877 patients
with diabetes Type 2 (ADA criteria),
collection of urine samples. Cross-sectional
study in the out-patient department of
seven public hospitals
18.5% normo-albuminuria, 35.5%
micro-albuminuria, 48% macro-albuminuria
Microalbuminuria 28.7%, macroalbuminuria 5.7%,
85% of them were non-DR and 15% DN and DR
including 8% with both DN and DR
Study year: March-October 2007 [53]
Setting: 13 primary care units in urban areas
Sample and study design: 287 diabetes
patients, 79 males, 208 females.
Cross-sectional study, ADA criteria
Prevalence of DN 48.3% (Type 1) and 31.8% (Type 2) Study year: April-December 2003 [67]
Setting: 11 tertiary diabetes centres
Sample and study design: Children and
adolescents diabetes, 58 Type 1 and 22 Type 2,
were screened for nephropathy. Cross-sectional
study. Thailand diabetes registry project
Prevalence of DN was 42.9%: 19.7% micro-
albuminuria, 23.2% overt nephropathy.
Study year: April-December 2003 [73]
Setting: 11 tertiary centres
Sample and study design: 4,875 diabetes
patients, 63.8% females. Cross-sectional study,
hospital based study. Thailand diabetes
registry project
Prevalence of DN 17% Study year: 2001 [15]
Setting: 8 provincial hospitals plus 4-5 district
hospitals providing primary health care
services in each province. Total number of sites: 37
Sample and study design: 1,078 diabetes
patients (300 males, 778 females).
Cross-sectional study
Vascular complications
Previous history of any lower extremity amputation:
0.9% right foot lesion, 0.6% left foot lesion
Study year: Aug 2005-March 2007 [74]
Diminished or absent pedal pulses 7.4% right foot
lesion, 7.7% left foot lesion
Setting: Diabetic clinic in a university hospital
in Northern Thailand
Low-risk ulcerative foot 3.7% Sample and study design: 438 diabetic patients.
Baseline data of patients attending the clinic
were collected
High-risk ulcerative foot 0.2%
1.2% acute foot ulcer/gangrene, 6.9%
healed foot ulcer
Study year: 2001 [15]
1.9% stroke, 0.7% myocardial infarction Setting: 8 provincial hospitals plus 4-5 district
hospitals providing primary health care
services in each province. Total
number of sites: 37
Sample and study design: 1,078 diabetes
patients (300 males, 778 females).
Cross-sectional study
Diabetic foot 40% (n = 50), cardiovascular disease
28.9% (n = 201), cerebrovascular disease
10.6% (n = 74)
Study year: 1 Jan-31 Dec 2006 [49]
Sample and study design: 722 diabetes patients,
Retrospective review of medicinal records of
DMT2 patients
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Table 3 Prevalence of diabetes complications in Thailand (Continued)
DM duration more than 15 years vs.
DM duration
less than 15 years group
Study year: April-December 2003 [66]
DN 49.4% vs. 33.9%, DR 54.3% vs. 22.8%;
myocardial
infarction 9.4% vs. 3.5%, peripheral
arterial disease,
17.3% vs. 5.5%, foot ulcer 13.4% vs. 5.3%,, stroke
9.4% vs. 7.0% and amputation 5.5% vs. 2.0%; all
p values less than 0.01).
Setting: 11 tertiary diabetes centres
Sample and study design: 9,284 adult diabetes
Type 2 patients registered to the Diabetes
registry project, 2,244 patients with duration
of diabetes more than 15 years and 7,040
patients with duration of diabetes less than
15 years. The longer duration group was on
average older than the shoter duration group.
Cross-sectional study. Thailand
diabetes registry project
Ischaemic heart disease 8.1% (n = 761) Study year: April-December 2003 [13]
Cerebrovascular 4.4% (n = 415) Setting: 11 tertiary care medical centres
Peripheral vascular disease 11.4%
(including amputation 1.6%, foot ulcer,
and absence of peripheral pulse)
Sample and study design: 9,419 diabetic
patients, 65.9% females, 94.6% DMT2, 4.5%
DMT1, 0.1% MODY. Cross-sectional, hospital
based study. Thailand diabetes registry project
Chronic kidney disease (CKD)
Prevalence of CKD stage 3 to 5 was
27.09% (n = 194) and 25.38% (n = 181)
using Cockcroft-Gault formula and
Modification of Diet in Renal Disease
(MDRD) formula respectively
Study year: April- August 2007 [51]
Setting: Six primary health care units in Udon
Thani province
Sample and study design: 714 diabetic patients,
542 females and 174 males. Cross-sectional
study, cluster random sampling method
CKD stage 1 23.2% (n = 113), stage
2 28.7% (n = 140), stage 3 37.3 (n = 182),
stage 4 8.2% (n = 40), stage 5 2.7% (n = 13)
Study year: 1 Jan-31 Dec 2006 [49]
Setting: 1 tertiary hospital, out-patient department
Sample and study design: 722 diabetes patients.
Retrospective review of medical records of
DMT2 patients
7.7% patients had renal insufficiency and
0.47% end-stage renal disease
Study year: April-December 2003 [73]
Setting: 11 tertiary centres
Sample and study design: 4,875 patients,
63.8% females. Cross-sectional study, hospital
based study.
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ance of monitoring and self-management, etc.)
Incidence of type 1 in children
Data on diabetes type 1 in Thai children aged 0-15 sug-
gests an increased incidence over the last 20 years from
less than 0.3 cases per 100,000 in 1984 in all regions to
1.27 cases per 100,000 in the North-East region in 2005.
However, interpretation of this data requires caution.
Apart from the Bangkok study, all the other studies
restricted their data collection to hospitals. Incidence
was calculated by dividing the total number of cases
reported by hospitals with the total child population inthe hospitals’ catchment area. Although hospitals’ re-
sponse rate was generally high (range: 84.7% to 94.5%)
[22,25], this means that in addition to not capturing dia-
betes type 1 cases who did not attend a hospital, the re-
sults were also importantly influenced by missing data
from hospitals that did not participate in the survey.
Under-diagnosis is likely to have played a major role
in the 1990s and first half of the 2000s because of in-
complete insurance coverage which created barriers to
health care access. Furthermore, apart from the North-
East region, no data is available after 1997 and the most
recent incidence data for the North-East region are
for 2005.
Table 4 Control of diabetes and of HbA1c levels
Estimate Summary of the main
features of the study
Reference
HbA1c levels <7% Study year: March-October 2007 [53]
41.3% Setting: 13 primary care units
in urban areas
Sample and study design:
287 diabetic patients, 79 males,
208 females. Cross-sectional study,
ADA criteria
HbA1c levels <7% Study year: July 2007 [72]
29.7% Setting: diabetes clinic in a
community hospital
Sample and study design:
325 diabetic patients (who had
diabetes for at least one year),
114 males, 221 females.
Cross-sectional study.
30.2% of the
participants achieved
HbA1c levels of
less than 7%
Study year: April-December 2003 [71]
Setting: 11 tertiary diabetes centres
Sample and study design: 8,913
Type 2 diabetes patients aged 18
and older (3,012 males and 5,901
females). Cross-sectional study.
Thailand diabetes registry project
HbA1c levels < 7% Study year: April-December 2003 [67]
DMT1: 17% Setting: 11 tertiary diabetes centres
DMT2: 21.6% Sample and study design: Children
and adolescents diabetes, 58 Type 1
and 22 Type 2, Cross-sectional study.
Thailand diabetes registry project
HbA1c levels 7-8%
DMT1: 20%
DMT2: 15.2%
HbA1c levels 8-9%
DMT1: 15%
DMT2: 15.2%
HbA1c levels >9%
DMT1: 47.6%
DMT2: 48.2%
Notes: standard deviation (SD).
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The latest data on the incidence of DMT2 in Thai adults
show an incidence rate of 13.6 in men per 1000 PY and
6.4 per 1000 PY in women [18]. However this data is
out-of-date as it refers to the time period 2001 to 2005
and is not representative of the entire country as it based
on urban high-socio-economic status individuals work-
ing in the healthcare sector.
Gestational diabetes
Due to different gestational weeks and age of the pro-
spective mother when the glucose test was conducted, it
is not possible to draw definitive conclusions on theevolution of the prevalence of GDM over time. Data only
included women attending antenatal care which might be
biased towards higher socio-economic groups due to the
lack of universal coverage at the time of the surveys. Des-
pite these challenges, two main findings seem to emerge.
First, a very large difference (eleven-fold) was reported
when using different diagnostic criteria (NDDG (1.4%) vs.
WHO criteria (15.7%)) on the same sample of women
and another recent study that used the new criteria of
international association of the diabetes and pregnancy
study groups (IADPSG) found the prevalence of GDM in
Bangkok was 23.0% [58]. Second, use of eligibility criteria
which limit screening to women at high risk of developing
GDM independently of their age have shown to miss more
than 50% of cases among women aged 30 and over.
Costs
Data on the cost of diabetes without complications mainly
comes from a study in one-hospital in North-East Thailand.
Generalisability of local studies on cost of illness is affected
by variation of input prices across the country, the level of
care of the hospital analysed, and the patient status. One
study in Thailand for example showed that a visit to the
regional hospital was 3.48 times more expensive than a
visit to a community hospital (THB 1,181 vs. THB 339 in
2002) [59]. Another issue was the uncertainty and large
variation around the results (very large standard deviations
were reported).
Complications and cost of complications
According to data from the Thailand diabetes registry,
diabetic nephropathy was the most common complica-
tion accounting for 43.9% of all complications followed
by retinopathy (30.7%), ischaemic heart disease (8.1%),
and cerebrovascular disease (4.4%) [13]. Another study
in the out-patient department of a university hospital
found a lower prevalence for diabetic nephropathy, 37%,
a similar prevalence for retinopathy, 31.2% but a sub-
stantially higher prevalence for cardiovascular and cere-
brovascular disease, 28.9% and 10.6%, respectively.
The first study also highlighted the existence of high
prevalence of risk factors for diabetes and its complica-
tions (dyslipidaemia, hypertension, and obesity (BMI ≥
25 kg/m2) was 73.3%, 63.3%, and 52.6% respectively) [13].
Complications are the single largest driver of the cost
of diabetes because they require more intensive care
such as hospitalisation and often surgery. Studies showed
that the median cost of illness for patients with complica-
tions in comparison to patients without complications
was USD$ 480 vs. USD 115 [37], USD$ 190 for diabetic
foot, USD$ 260 for cerebrovascular event, USD$ 336 for
gangrene in comparison to USD$ 101 for patients without
complications [52]. Interestingly, the latter study which
was based on retrospective data analysis and cost forecast,
Table 5 Cost of diabetes complications in Thailand
Cost of complications Summary of the main features of the study References
Median cost per year (USD$ at 2008
prices) of diabetes for patients:
Study year: 2007-2008 [60]
With complications: USD$ 480
(n = 148, SD = 3,023)
Setting: Waritchaphum hospital in Sakhon
Nakhon province (North-East Thailand)
Without complications: USD$ 115
(n = 327, SD = 2,648)
Sample and study design: 475 randomly
selected diabetic patients
Independent: USD$ 124
(n = 411, SD = 2,152)
Any level of disability: USD$ 811
(n = 61, SD = 4,982)
Mildly disabled: USD$ 668
(n = 51, SD = 3,848)
Moderate disability: USD$ 2,374
(n = 7, SD = 7,940)
Severely disabled: USD$ 4,891
(n = 1, SD = 0)
Very severely disabled: USD$ 4,378
(n = 5, SD = 7,622)
Average spending per hospital
admission as percentage of GDP per
capita and in USD (constant 2000):
Study year: 2006-2008 [61] USD equivalents of the percentage
of GDP spent per hospital admission
were calculated by the authors using
GDP data (USD constant 2000, 2,712
in 2007) from The World Bank.Total: 62% (USD$ 1682) Setting: University hospital in Bangkok
without complications: 49% (USD$ 1,329) Sample and study design: The study
included all 8,596 (94% insured, 6%
uninsured) DM patients admitted in
the hospital during 2006-2008.
Retrospective data analysis.
with myocardial infarction:
108% (USD$ 2,930)
with congestive heart failure:
93% (USD$ 2523)
with peripheral vascular disease:
116% (USD$ 3147)
with ulcer: 106% (USD$ 2,876)
with hemiplegia: 63% (USD$ 1,709)
with moderate/severe renal disease:
90% (USD$ 2,442)
Median cost of illness per year: Study year: 2007-2008 [37] same study as [60]
With complications USD$ 480
(n = 148, IQR = 129-1552)
Setting: Waritchaphum hospital in Sakhon
Nakhon province (North-East Thailand)
Without complications USD$ 115
(n = 327, IQR = 74-286)
Sample and study design: 475
randomly selected diabetic patients.
Micro-costing approach.
With microvascular complications
USD$ 641 (n = 59, IQR = 207-2,268)
With macrovascular complications
USD$ 367 (n = 11, IQR = 111-2,463)
With micro- and macrovascular
complications USD$ 666
(n = 11, IQR = 201-2,707)
With microvascular complications
and cataract USD$ 745 (n = 23, IQR = 376-1,358)
Cataract USD$ 151 (n = 44, IQR = 94-587)
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Table 5 Cost of diabetes complications in Thailand (Continued)
Predicted cost per year of DM T2 (N = 186): Study year: 2001 [52]
without complications USD$ 101
(BHT 4,037)
Setting: 30-bed public hospital
in central Thailand
with hypertension USD$ 117
(BHT 4,686)
Sample and study design: 186 diabetic
patients. Retrospective prevalence-based
cost of illness study. Multiple regression
analysis was used to predict cost of DM
for various types of complications.
with hyperlipidaemia USD$ 144
(BHT 5,775)
with diabetic foot USD$ 190
(BHT 7,603)
with hyperglycaemia USD$ 209
(BHT 8,369)
with hypoglycaemia USD$ 247
(BHT 9,860)
with cerebrovascular accident USD$
260 (BHT 10,418)
with gangrene USD$ 336 (BHT 13,417)
(40 THB = 1 USD$ at 2011 prices)
Notes: SD: standard deviation, IQR: inter-quartile range.
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caused by pharmacy services (45%) followed by outpatient
(24%) and inpatient services (16%) [52]. The first study
found a similar share of inpatient costs (11%) but in
addition to direct costs it also estimated indirect costs and
the contribution of informal care, mortality, and perma-
nent disability to the cost of illness (27.8%, 17.5%, 18.7%,
respectively) [37] (Table 5). This data shed some light on
substantial indirect costs caused by morbidity and reduced
ability to work. Preventing complications, and related dis-
ability, by improving diabetes control is therefore of para-
mount importance to reduce the health and economic
burden of diabetes.
There is a large variation in the estimates of the preva-
lence and costs of complications in Thailand. More stud-
ies at different levels of care and covering all the regions
are needed to get a full picture of the prevalence and the
cost of diabetes complications in the country.Conclusions
Based on the results of this study, the following priorities
for the future management of diabetes in Thailand were
identified. First, increasing screening of diabetes in high
risk population and promoting annual screening of dia-
betes complications in all diabetic patients. Second, identi-
fying and addressing factors affecting poor treatment
outcomes in light of reducing the number of treated but
not controlled patients and therefore reducing their likeli-
hood of developing complications. Third, policy should
specify clear targets and provide and use a monitoring
framework to track progress.Fourth, efforts are needed to further improve data avail-
ability. Up-to-date data on the medical and economic bur-
den of diabetes representative at the national level and at
least the regional level are essential to identify needs and
monitor progress towards established targets. Priority
areas for data collection include incidence of diabetes in
children and adults, prevalence of GDM, cost of diabetes
and its complications, and treatment compliance and out-
comes at individual level. Availability of prevalence data is
good due to the regular NHES, however, these surveys are
only conducted every 5-7 years.
Fifth, promotion of a healthy lifestyle for prevention of
diabetes through education and quality information de-
livered to the public.
Efforts to address these issues have already started in
some areas of the country but not overall. In order to
achieve this, a multisectoral effort including concerted
policy actions from a variety of policy makers (beyond
the ministry of public health and including other rele-
vant ministries) and of public opinion leaders as well as
interventions involving public and private delivery chan-
nels is required.
Endnotes
aStudy year is not specified but the publication data is
2000 so it is very likely to refer to the late 1990s.
bIn 2004 prevalence in urban areas was higher for men
but not for women.
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